Aurobindo Pharma's subsidiary CuraTeQ Biologics Secures MHRA Approval for Trastuzumab Biosimilar Dazublys in HER2-Positive Cancer
Hyderabad: CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma Ltd., has secured marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys, its trastuzumab biosimilar.
This approval follows the earlier marketing authorisation in the European Union by the European Commission in July 2025. Dazublys marks CuraTeQ’s fourth biosimilar to receive MHRA approval, after Bevqolva in December 2024, Zefylti in May 2025, and Dyrupeg in June 2025.
Notably, Dazublys, Zefylti, and Dyrupeg are also cleared for sale in the European Union.
Also Read: Aurobindo Pharma Arm CuraTeQ Biologics Incorporates News Wholly Owned Subsidiary in Netherlands
Dazublys is a biosimilar version of trastuzumab, used for the treatment of HER2-positive breast cancer and certain types of gastric cancer. It works by targeting the HER2 receptor on cancer cells, helping to slow or stop their growth.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.